Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc (NYSE: PHGE) is a clinical-stage biotechnology company pioneering phage therapies targeting harmful bacteria in chronic diseases. This page serves as the definitive source for verified news and official announcements related to the company’s scientific advancements, clinical trials, and strategic partnerships.
Investors and researchers will find timely updates on key developments including phage therapy milestones, regulatory progress, and microbiome research collaborations. The curated collection features press releases covering clinical trial outcomes, manufacturing updates, and peer-reviewed study publications.
All content undergoes strict verification to ensure alignment with financial disclosure standards. Users can expect comprehensive coverage of BiomX’s innovative pipeline, including its BOLT platform developments and therapeutic candidates for conditions like cystic fibrosis and inflammatory bowel disease.
For stakeholders tracking progress in precision microbiome treatments, we recommend bookmarking this page for direct access to BiomX’s latest scientific achievements and corporate announcements. Check regularly for authoritative updates from this leader in engineered phage therapeutics.
BiomX (NYSE American: PHGE) announced the publication of a scientific paper on the Exodus algorithm, enhancing the identification of genetically-related microorganisms. The Exodus algorithm improves the quantification of pooled genomes, achieving median error rates between 0% and 0.21%. Notably, the algorithm recorded no false negatives, indicating high accuracy even with low-abundance genomes. This advancement is expected to optimize the detection of virus variants and aid in the analysis of various genomic projects.
BiomX (PHGE) has made significant strides in its pipeline, particularly in treating cystic fibrosis (BX004) and atopic dermatitis (BX005). The Phase 1b/2a trial for BX004 is set to begin, with initial results expected by Q3 2022. The IND for BX005 has been approved, with data readouts anticipated in Q4 2022. Financially, the company reported a cash balance of $55.7 million as of March 31, 2022, down from $63.1 million, primarily due to operating expenses. Despite a net loss of $8.2 million, the cash runway is projected to last through 2023.
BiomX Inc. (NYSE American: PHGE) will host a virtual key opinion leader webinar on May 12, 2022, at 11:00 AM EDT to discuss BX004, a phage therapy aimed at treating Pseudomonas Aeruginosa infections in cystic fibrosis patients. The FDA cleared BX004 for a Phase 1b/2a trial in September 2021, with initial data expected in Q3 2022. Key Opinion Leaders Dr. Dave Nichols and Dr. Saima Aslam will present, followed by BiomX CEO Jonathan Solomon. Registration is available on BiomX's website.
BiomX (NYSE American: PHGE) will host a conference call on
BiomX (NYSE: PHGE) reported its financial results for Q4 and the full year 2021, revealing a cash position of $63.1 million, up from $57.1 million in 2020. The company anticipates major clinical data readouts in 2022 for its cystic fibrosis (BX004) and atopic dermatitis (BX005) therapies. BiomX’s current cash runway supports operations through 2023, with potential for extension to mid-2024 via venture debt. The net loss for 2021 stood at $36.2 million, marking an increase from $30.1 million in 2020. A conference call is scheduled for today at 8:00 am ET.
BiomX Inc. (NYSE American: PHGE) has announced a conference call scheduled for March 30, 2022, at 8:00 a.m. EDT to discuss its fourth quarter and full year 2021 financial results along with business updates. The company specializes in developing natural and engineered phage therapies targeting bacteria linked to chronic diseases like cystic fibrosis and colorectal cancer. Investors can access the live webcast via biomx.com.
BiomX (NYSE American: PHGE) has announced that CEO Jonathan Solomon will present at three notable conferences in 2022. These include the Aegis Virtual Conference on February 24, the Chardan 4th Annual Microbiome Medicines Summit on March 1, and the Oppenheimer & Co. 32nd Annual Healthcare Conference on March 17. The presentations will highlight the company's development of innovative phage therapies targeting pathogenic bacteria related to various chronic diseases. Live webcasts will be available on BiomX's website.
BiomX (AMEX: PHGE) has announced a $5 million funding from the Cystic Fibrosis Foundation to support its Phase 1b/2a study of BX004, targeting chronic respiratory infections in cystic fibrosis patients. The funding will be provided in two tranches: an initial $3 million received in December 2021 and a potential additional $2 million upon completion of patient dosing. The study aims to assess the therapy's safety and efficacy, with results expected in 2022.
BiomX Inc. (PHGE), a clinical-stage microbiome company, announced its participation in two upcoming healthcare events: the Jefferies London Healthcare Conference from November 18-19, 2021 and the 2021 Phage Futures Congress Europe on November 23-24, 2021. At the Jefferies conference, an on-demand session will be presented by Jonathan Solomon, available from November 18. The Phage Futures Congress will feature a presentation titled “Nebulized Bacteriophage Therapy” by Myriam Golembo, Ph.D. on November 23. Webcasts will be accessible via the company's website.
BiomX (PHGE) announced a strategic shift to focus on its cystic fibrosis and atopic dermatitis programs, aiming for proof-of-concept data in 2022. The company has extended its cash runway to the end of 2023, supported by FDA clearance for its Phase 1b/2a trial in cystic fibrosis. BiomX will discontinue its acne program and postpone developments in inflammatory bowel disease and colorectal cancer.
As of September 30, 2021, BiomX reported a cash balance of $68.3 million and a net loss of $10 million for Q3 2021.
FAQ
What is the current stock price of Biomx (PHGE)?
What is the market cap of Biomx (PHGE)?
